8-K: Viking Therapeutics Reports Q2 2025 Results, Advances Obesity Drug Programs

Viking Therapeutics announced its second quarter 2025 financial results, highlighting the initiation of Phase 3 trials for subcutaneous VK2735 in obesity and completion of enrollment for the oral VK2735 Phase 2 study, alongside increased net losses.

Summary

• Initiated Phase 3 VANQUISH registration program for subcutaneous VK2735 in obesity, comprising two studies: VANQUISH-1 (obesity) and VANQUISH-2 (obesity/overweight with type 2 diabetes).
• Completed enrollment for the Phase 2 VENTURE-Oral Dosing study of oral VK2735, with top-line results expected in the second half of 2025.
• Continued progress with the dual amylin and calcitonin receptor agonist (DACRA) program, with an Investigational New Drug (IND) application planned for Q4 2025.
• Reported a net loss of $65.6 million ($0.58 per share) for Q2 2025, compared to a net loss of $22.3 million ($0.20 per share) for Q2 2024.
• Reported a net loss of $111.2 million ($0.99 per share) for the six months ended June 30, 2025, compared to a net loss of $49.6 million ($0.46 per share) for the same period in 2024.
• Research and development expenses increased to $60.2 million in Q2 2025 from $23.8 million in Q2 2024, and to $101.5 million for the six months ended June 30, 2025, from $47.9 million in the same period in 2024.
• General and administrative expenses increased to $14.4 million in Q2 2025 from $10.3 million in Q2 2024, and to $28.5 million for the six months ended June 30, 2025, from $20.3 million in the same period in 2024.
• Maintained a strong cash, cash equivalents, and short-term investments position of $808 million as of June 30, 2025, down from $903 million as of December 31, 2024.

Sentiment

Score: 6

Explanation: While financial losses increased significantly due to R&D expansion, the core news is the positive advancement of key drug candidates (VK2735 into Phase 3, oral VK2735 enrollment completion, and DACRA IND planning) and a strong cash position. The increased expenses are a direct result of clinical progress, which is generally viewed positively for a clinical-stage biopharmaceutical company, albeit with increased burn rate.

Positives

• Initiation of Phase 3 VANQUISH registration program for subcutaneous VK2735, indicating significant clinical advancement.
• Completion of enrollment for the Phase 2 VENTURE-Oral Dosing study of oral VK2735, demonstrating rapid progress and strong demand for weight loss therapies.
• Strong quarter-end cash position of $808 million, providing sufficient runway to support Phase 3 clinical trials and other development programs.
• Continued progress with the dual amylin and calcitonin receptor agonist (DACRA) program, with an IND filing planned for Q4 2025.
• Prior positive Phase 2 VENTURE study results for subcutaneous VK2735, showing statistically significant body weight reductions up to 14.7% after 13 weeks.
• Prior positive Phase 1 multiple ascending dose trial results for oral VK2735, showing dose-dependent weight reductions up to 8.2% after 28 days.

Negatives

• Net loss significantly increased to $65.6 million in Q2 2025 from $22.3 million in Q2 2024.
• Net loss for the six months ended June 30, 2025, increased to $111.2 million from $49.6 million in the same period in 2024.
• Significant increase in research and development expenses due to increased clinical studies and manufacturing costs.
• Increase in general and administrative expenses.
• Decrease in cash, cash equivalents, and short-term investments to $808 million from $903 million at year-end 2024.

Risks

• Risks associated with the success, cost, and timing of product candidate development activities and clinical trials, including for VK2735, VK0214, VK2809, and other incretin and receptor agonists.
• Risks that prior clinical and preclinical results may not be replicated in future studies.
• Risks regarding regulatory requirements and approvals.
• Other risks described in Viking's most recent periodic reports filed with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

Viking Therapeutics expects to announce top-line data from the Phase 2 VENTURE-Oral Dosing study in the second half of 2025. The company also plans to submit an Investigational New Drug (IND) application for its dual amylin and calcitonin receptor agonist (DACRA) program in the fourth quarter of 2025. The strong cash position is anticipated to support the advancement of VK2735 through Phase 3 clinical trials and other key development programs.

Management Comments

• "The Viking team achieved significant execution and clinical milestones during the first half of 2025."
• "We recently announced the initiation of the VANQUISH Phase 3 registration program, consisting of two studies: one in patients with obesity and one in patients with obesity and type 2 diabetes."
• "We announced both the initiation and completion of enrollment in the Phase 2 VENTURE-Oral Dosing study of our oral tablet formulation of VK2735. We believe the study's rapid enrollment speaks to continued strong demand for new and differentiated weight loss therapies."
• "We remain on track to announce top-line data from the VENTURE-Oral study in the second half of the year."
• "With respect to our amylin agonist program, we continue to make progress toward an IND filing, which we expect to submit later this year."
• "Importantly, we completed the second quarter with a strong balance sheet providing the runway to support the advancement of VK2735 through Phase 3 clinical trials, in addition to supporting further progress with other key development programs."

Industry Context

This announcement highlights Viking Therapeutics' continued focus on the highly competitive and rapidly expanding market for metabolic and endocrine disorders, particularly obesity. The advancement of VK2735, a dual GLP-1/GIP agonist, into Phase 3 trials positions Viking as a significant player alongside established and emerging companies developing similar incretin-based therapies. The development of both subcutaneous and oral formulations addresses different patient preferences and market segments, reflecting a strategic approach to maximize market penetration in a landscape dominated by injectables. The progress in the amylin agonist program also indicates diversification within the obesity therapeutic area, exploring novel mechanisms of action.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards. However, the rapid enrollment in the Phase 2 VENTURE-Oral Dosing study, as noted by management, suggests strong market interest and demand for new weight loss therapies, aligning with broader industry trends seen with other successful GLP-1/GIP agonists.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if clinical trials are successful, but increased short-term losses and cash burn.
• Patients: Potential for new, effective treatment options for obesity and metabolic disorders, including both injectable and oral formulations.
• Employees: Continued employment and potential growth opportunities due to advancing pipeline.
• Creditors: No specific impact mentioned, but strong cash position reduces immediate credit risk.
• Suppliers/Partners: Increased demand for clinical trial services and manufacturing.

Next Steps

• Announce top-line data from the Phase 2 VENTURE-Oral Dosing study in the second half of 2025.
• Submit an Investigational New Drug (IND) application for the dual amylin and calcitonin receptor agonist (DACRA) program in the fourth quarter of 2025.
• Provide further updates on the VANQUISH Phase 3 program as studies progress.
• Management participation in upcoming investor events: BTIG Virtual Biotechnology Conference (July 29-30, 2025), Cantor Global Healthcare Conference (September 3-5, 2025), Morgan Stanley 23rd Annual Global Healthcare Conference (September 8-10, 2025), Bernstein's 2nd Annual Healthcare Forum (September 23-25, 2025), Stifel 2025 Virtual Cardiometabolic Forum (September 30, 2025).

Key Dates

Recommendation

While the significant progress in advancing VK2735 into Phase 3 and the completion of enrollment for the oral formulation are strong positive catalysts, the increased net losses and cash burn reflect the high costs of late-stage clinical development. The company has a strong cash position to fund these activities, mitigating immediate financial concerns. However, the stock's performance will heavily depend on the upcoming top-line data from the oral VK2735 study and the long-term success of the Phase 3 program, which carries inherent clinical and regulatory risks. Given the current stage of development and the balance of positive clinical momentum against increased expenses and future trial uncertainties, a 'hold' recommendation is appropriate, awaiting further clinical data and regulatory clarity.

Keywords

Viking Therapeutics, VK2735, Obesity, GLP-1, GIP, Weight Loss, Clinical Trials, Phase 3, Phase 2, Biopharmaceutical, Metabolic Disorders, Amylin Agonist, DACRA, Financial Results, Biotechnology, Drug Development, Clinical-stage, VANQUISH, VENTURE-Oral, IND Filing